| Market Cap | 656.81M | P/E | - | EPS this Y | 22.70% | Ern Qtrly Grth | -92.60% |
| Income | -83M | Forward P/E | 19.28 | EPS next Y | 29.60% | 50D Avg Chg | 4.00% |
| Sales | 1.04B | PEG | -0.52 | EPS past 5Y | - | 200D Avg Chg | -2.00% |
| Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | -61.60% | 52W High Chg | -23.00% |
| Recommedations | 3.10 | Quick Ratio | 1.41 | Shares Outstanding | 50.04M | 52W Low Chg | 25.00% |
| Insider Own | 2.32% | ROA | 1.55% | Shares Float | 43.98M | Beta | - |
| Inst Own | 112.03% | ROE | -10.98% | Shares Shorted/Prior | 3.06M/3.53M | Price | 13.11 |
| Gross Margin | 48.52% | Profit Margin | -7.95% | Avg. Volume | 685,529 | Target Price | 9.32 |
| Oper. Margin | 4.92% | Earnings Date | - | Volume | 390,052 | Change | -3.46% |
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
| Leerink Partners | Market Perform | May 14, 24 |
| Jefferies | Hold | May 9, 24 |
| TD Cowen | Market Perform | Mar 11, 24 |
| Oppenheimer | Perform | Mar 7, 24 |
| UBS | Neutral | Mar 7, 24 |
| Jefferies | Buy | Mar 6, 24 |
| TD Cowen | Market Perform | Dec 12, 23 |
| Credit Suisse | Neutral | Aug 11, 23 |
| Goldman Sachs | Neutral | Jul 17, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bolton Jeffrey | Director Director | May 26 | Buy | 11.61 | 2,000 | 23,220 | 19,597 | 05/31/23 |
| SHAW L EDWARD JR | Director Director | May 22 | Buy | 11.98 | 10,000 | 119,800 | 38,989 | 05/23/23 |
| Hoeflinger Erin | Director Director | May 18 | Buy | 11.82 | 2,100 | 24,822 | 15,697 | 05/22/23 |
| Langham Ronald Leroy JR | EVP Clinical Excel... EVP Clinical Excel. & Strategy | May 18 | Buy | 11.99 | 10,000 | 119,900 | 44,328 | 05/22/23 |
| Bolton Jeffrey | Director Director | Nov 18 | Buy | 12.69 | 1,000 | 12,690 | 15,597 | 11/22/22 |
| Bolton Jeffrey | Director Director | Nov 08 | Buy | 12.82 | 4,000 | 51,280 | 14,597 | 11/10/22 |
| HIGDON LEO I JR | Director Director | Nov 08 | Buy | 13.57 | 426 | 5,781 | 7,926 | 11/09/22 |
| Rush Gregory S | Director Director | Nov 04 | Buy | 12.64 | 10,000 | 126,400 | 16,597 | 11/08/22 |
| Brown-Stevenson Tina L. | Director Director | Aug 31 | Buy | 15.99 | 1,550 | 24,784 | 9,645 | 09/02/22 |
| Hoeflinger Erin | Director Director | Aug 18 | Buy | 13.76 | 7,000 | 96,320 | 13,597 | 08/22/22 |
| ELSON CHARLES M | Director Director | Aug 11 | Buy | 13.55 | 3,700 | 50,135 | 22,069 | 08/15/22 |
| MAUPIN JOHN E JR D D S | Director Director | Aug 08 | Buy | 13.59 | 1,000 | 13,590 | 17,390 | 08/10/22 |
| CURL YVONNE M | Director Director | Aug 08 | Buy | 13.75 | 1,500 | 20,625 | 17,608 | 08/10/22 |
| Jacobsmeyer Barbara Ann | President and CEO President and CEO | Aug 09 | Buy | 13.78 | 30,000 | 413,400 | 238,442 | 08/10/22 |
| SHAW L EDWARD JR | Director Director | Aug 09 | Buy | 13.64 | 10,000 | 136,400 | 28,989 | 08/10/22 |
| HIGDON LEO I JR | Director Director | Aug 04 | Buy | 12.37 | 3,000 | 37,110 | 7,500 | 08/08/22 |
| LaMonica Susan | Director Director | Aug 04 | Buy | 11.72 | 15,000 | 175,800 | 23,095 | 08/08/22 |
| Bolton Jeffrey | Director Director | Aug 04 | Buy | 11.74 | 1,000 | 11,740 | 7,597 | 08/08/22 |
| HIGDON LEO I JR | Director Director | Aug 03 | Buy | 13.57 | 4,500 | 61,065 | 4,500 | 08/05/22 |